51 results about "Hepatic function" patented technology

The disclosure provides a method for quantification of hepatic function in a subject comprising measuring the clearance of an orally administered isotopically labeled cholic acid in a subject with, or suspected of having or developing, a hepatic disorder, for example, chronic hepatitis C. The disclosure further provides methods and kits for assessment of hepatic function.

The invention belongs to the field of medicinal chemistry. Specifically, the invention relates to a prodrug containing a tiopronin structure showed by the following general formula I or a tautomer and a stereisomer of the prodrug, a stereisomer mixture or pharmaceutically acceptable solvate of the stereisomer mixture, a preparation method of the prodrug, a pharmaceutical composition, and application of the pharmaceutical composition serving as an anti-hepatitis c drug. This type of compounds or pharmaceutical compositions thereof can be used for curing hepatitis c, and also has the effects of protecting hepatic tissues and hepatic cells, and improving hepatic function.

A method for estimating portal blood flow and hepatic function in a subject is provided. In one example, the STAT test is an in vitro simplified, convenient test intended for screening purposes that can reasonably estimate the portal blood flow from a single blood sample taken 60 minutes after orally administered deuterated-cholate. The test can be administered to a patient having, or suspected of having, Chronic Hepatitis C, Primary Sclerosing Cholangitis (PSC), Non-Alcoholic Fatty Liver Disease (NAFLD), or any chronic liver disease.

Provided is a method of measuring blood coagulation time, the method being capable of LA detection easily and with high sensitivity as compared with the method recommended by the ISTH, without being affected by deficiency of blood coagulation factors even in a blood sample of a warfarin taker, a person who suffers from vitamin K deficiency, or a hepatic failure patient. Disclosed is a method of measuring the blood coagulation time to detect lupus anticoagulant, the method including adding a buffer solution composition containing blood coagulation factors to a blood sample before measurement or at the time of measurement of the blood coagulation time, and measuring the blood coagulation time.

The invention discloses a novel traditional Chinese medicine composition for treating cardiac carcinoma and a preparation method thereof. The traditional Chinese medicine composition mainly comprises the raw materials of lignum dalbergiae odoriferae, szechuan lovage rhizome, alosewood, costus root, pericarpium citri reticulatae, poria, frankincense, myrrh, Chinese lobelia herb, whiteflower patrinia herb, ground beetle, malayan pangolin, leech, rhubarb, Chinese goldthread, honeysuckle flower, philippine violet herb, grassleaf sweelflag rhizome, radix sophorae tonkinensis, medicated leaven, immature bitter orange, India madder root, dried ginger, peppermint, sophora flavescens ait, and the like. The traditional Chinese medicine composition can be prepared into any common oral preparation by the conventional preparation method of traditional Chinese medicines. The invention can obviously improve symptoms, such as upper gastrointestinal hemorrhage, food retention or non-smooth feeling, stomach pain, marasmus, anemia, edema, hepatic failure, coma, gastroduodenal obstruction, and the like and has definite and significant clinical curative effect and quick effectiveness. Because the traditional Chinese medicine composition is combined by medicaments which are specified as both food and medicine in a national pharmacopoeia basically, the invention has the advantages of low cost, almost no toxic or side effect, and the like.

The invention provides a composition for improving an in vivo metabolism parameter. A composition containing D-psicose as an active ingredient, which can be used for giving D-psicose at a dose of 5 g or more for each time continuously for the purpose of decreasing an in vivo metabolism parameter, i.e., a uric acid level and / or a level of a hepatic function indicator component. The level of 15 g gamma-GTP is significantly decreased from week 4 of the ingestion of the composition. When the composition is given continuously at a dose of 5 g or more in terms of D-psicose content three times a day, the level of gamma-GTP is significantly decreased from week 4 of the ingestion of the composition and the level of ALP is significantly decreased from week 2 of the ingestion of the composition.

The invention belongs to the field of pharmaceutical chemistry and particularly relates to a tiopronin structure containing prodrug represented by a general formula I shown in the description or tautomers, stereomers, stereomer mixtures or pharmaceutically-acceptable solvates thereof, preparation methods for the prodrug or the tautomers, stereomers, stereomer mixtures or pharmaceutically-acceptable solvates thereof, pharmaceutical compositions and use of the pharmaceutical compositions as hepatitis C resisting drugs. The compounds or pharmaceutical compositions thereof can be applied to the treatment of hepatitis C and meanwhile play roles in protecting hepatic tissue and hepatic cells and improving hepatic functions.

The invention belongs to the field of medicines, and provides a medicine for treating acute liver failure. The invention discovers that a compound kinsenoside (Kinsenoside(3-(R)-3-beta-D-Glucopyranosyloxybutanolide) can effectively prevent the development of acute liver failure, and in a mouse liver failure model, the compound has the activities of improving liver function and oxidative stress injury, and reducing inflammatory factor secretion and the like; and meanwhile, hepatic cell apoptosis is inhibited by protecting the structural integrity of mitochondria, so that the compound has remarkable liver protection activity and can be used as a medicine for treating the acute liver failure for treating the acute liver failure.

Provided is a method of preparing a three-dimensional cell spheroid, the method including forming the cell spheroid by co-culturing adipose-derived stem cells or mesenchymal stem cells with hepatocytes. According to the cell spheroid prepared by the method, the secretome secreted by the adipose-derived stem cells affects hepatocyte maturation, and therefore, hepatic functions of the finally formed three-dimensional cell spheroid, i.e., organoid, may be enhanced. Further, a composition including a culture medium of the adipose-derived stem cells may prevent or treat liver diseases including hepatitis, hepatotoxicity, cholestasis, fatty liver, etc., and may enhance hepatic functions.

The invention discloses an in-vitro liver perfusion device which comprises a support, a clamping mechanism, a hepatic portal vein perfusion channel and a hepatic artery perfusion channel, wherein the clamping mechanism is arranged on the support and is used for clamping a ligament of the in-vitro liver so as to hang the in-vitro liver; the hepatic portal vein perfusion channel is slidably arranged on the support, and one end of the hepatic portal vein perfusion channel is communicated with a hepatic portal vein of the in-vitro liver; the hepatic artery perfusion channel is slidably arranged on the hepatic portal vein perfusion channel, and one end of the hepatic artery perfusion channel is communicated with the hepatic artery of the in-vitro liver. The ligament of the in-vitro liver is clamped through the clamping mechanism arranged on the support, so that the in-vitro liver is hung, the in-vitro liver is in a free sagging state, the whole in-vitro liver is not extruded, and the situation that the liver function is damaged due to stacking of the in-vitro liver when the in-vitro liver is directly contained in a container is prevented; and the hepatic portal vein perfusion channel and the hepatic artery perfusion channel are arranged, so that a perfusion tube can be conveniently inserted and is not easy to fall off, and perfusate can be prevented from leaking at the insertion part.

A simulation system for simulating functions of biological organs, comprising a biological model in which the functions of the biological organs are expressed by mathematical models. The biological model comprises a hepatic metabolism model block having specified input and output relating to hepatic function for simulating the hepatic function. The system further comprises arithmetic means for calculating an output value by using measurable status variables of a liver based on input value to the hepatic metabolism model block.

The invention relates to compositions and methods using various combinations of at least one of phytosterols, lunasin peptide and plant extracts, optionally in combination with at least one of, soy extracts, beta-glycolipides and different adjuvants such as, castor oil, polyethylene glycol, or beta-cyclo dextrin, for controlling blood sugar levels, altered insulin resistance and / or hepatic function in a subject, treating an immune related disorder, treating liver damage and restoring liver function, treating, preventing, ameliorating, reducing or delaying the onset of acute or chronic toxic effect of a drug, and for enhancing the therapeutic effect of a therapeutic agent in a subject.